



IDS-iSYS Salivary Cortisol

The IDS-iSYS Salivary Cortisol assay is an *in vitro* diagnostic immunoassay intended for the quantitative determination of cortisol in human saliva on the IDS-iSYS Multi-Discipline Automated System family. Results are to be used as an aid in the assessment of Cushing's syndrome and other disorders of the hypothalamic pituitary adrenal axis.

Cortisol is a **steroid hormone** synthesised in the cortex of the adrenal gland. Approximately 90% of cortisol in plasma is protein-bound to cortisol-binding-globulin (CBG). Measurement of **unbound cortisol found in saliva** is an accurate method to assess the biologically **active free plasma cortisol**^{1,2}. CBG concentrations decrease with certain liver and kidney diseases, resulting in decreased serum cortisol concentrations. The unbound fraction (as in saliva) is said to remain constant³.

In healthy subjects, cortisol levels peak at 7–9 a.m., with levels falling for the rest of the day⁴. Patients with abnormal function of the adrenal gland lose normal **circadian rhythm** and have higher levels of cortisol at midnight⁵.

Measuring midnight salivary cortisol is an easy and non-invasive means of diagnosing diseases of cortisol imbalance such as **Cushing's syndrome (CS)**. Salivary cortisol is most useful as the initial test when CS is suspected and for periodic patient monitoring after pituitary surgery for Cushing's syndrome^{6,7}.

Clinical Value

- Bringing efficiency to automated cortisol clinical diagnostics in saliva patient samples - first result in 8 minutes
- Excellent sensitivity and reproducible results
- Accurate assay results with calibration to isotope dilution mass spectrometry (IDMS)
- A comprehensive clinical assay panel supporting diagnosis of endocrine hypertension disorders

Specifications

Format	Automated Chemiluminescence Immunoassay (CLIA)	
Limit of Quantitation	0.02 µg/dL	
Limit of Blank	0.015 ug/dL	
Assay Range	0.02 – 3.00 µg/dL	
Sample Volume	200 µL	
Sample Type	Saliva	
Calibration Stability	7 days	
Reagent On-board Stability	28 days	
Specificity	Dexamethasone <1% 6α-Hydroxycortisol <1% 6β-Hydroxycortisol <1% 6α-Methylprednisolone and Progesterone: <1% 11-Deoxycortisol and 11-Deoxycorticosterone: ≤ 5% Cortisone, Corticosterone, Prednisone and 21-Deoxycortisol: <20% Prednisolone: 28%	
Linearity	Observed = 0.97 Expected + 0.01µg/dL; R ² 0.99	
Recovery	Mean 93.4% at 0.313 and 0.626 µg/dL	
Reference Ranges	06:00 – 10:00	20:00 – 00:30
	No. of subjects	124
	Reference Interval (µg/dL)	0.09 – 1.04
		0.02 – 0.34

Ordering Information


Product Name	Code
IDS-iSYS Salivary Cortisol Reagent pack:	IS-4900
IDS-iSYS Salivary Cortisol Control Set	IS-4930
IDS-iSYS Salivary Cortisol Calibration Verifiers	IS-4935

Related Product

Product Name	Code
IDS-iSYS Aldosterone	IS-3300
IDS-iSYS Direct Renin	IS-3400

Method Comparison

Method comparison IDS-iSYS Salivary Cortisol Vs IBL ELISA



For more details on our products visit www.idsplc.com

References

- David W., The Immunoassay Handbook. Third Edition. D.Wild (Ed.) Published by Elsevier Ltd. 2005.
- Yaneva M., Mosnier-Pudar H., Dugue M-A., Grabar S., Fulla Y. and Bertagna X., 'Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome and various causes'. J Clin Endocrinol Metab, 89(7), 2004, pp 3345-3351.
- Aardal, E. and Holm, A-C., 'Cortisol in saliva – reference ranges and relation to cortisol in serum'. Eur J Clin Chem Clin Biochem, 33, 1995, 927-932.
- Rossi GP., Seccia TM. and Pessina AC., 'Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension'. Crit Rev Clin Sci, 44(1), 2007, pp 1-85.
- Nieman LK., Biller BMK., Findling JW., Newell-Price J., Savage MO., Stewart PM., and Montori VM., 'The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline'. J Clin Endocrinol Metab, 93, 2008, pp 1526-1540.
- Raff, H., 'Cushing's syndrome: diagnosis and surveillance using salivary cortisol'. Pituitary, 15, 2012, pp 64-70.
- Raff, H., 'Update on late-night salivary cortisol for the diagnosis of Cushing's syndrome: methodological considerations'. Endocrine, 44, 2013, pp 346-349